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Circulating biomarkers of neuroendocrine prostate
cancer: an unmet challenge
Prostate cancer is a global health issue and, although the
overwhelming majority (>95%) of metastatic castration-
resistant prostate cancers (CRPCs) have adenocarcinoma
histology [1], a subset of tumours acquire histopathological
and immunohistochemical evidence of neuroendocrine
differentiation, with a variety of morphological classiﬁcations
being reported [1]. Nonetheless, the term ‘neuroendocrine
prostate cancer’ (NEPC) should be reserved for tumours with
absent or minimal androgen-signalling modulated
transcription [2]. NEPC arising in the castration-resistant
scenario (treatment-related NEPC or tNEPC) [2] is a disease
of unknown prevalence and without an optimum treatment
regime. Autopsy studies have shown at least focal
neuroendocrine differentiation may be present in up to 33%
of patients [3]. The cellular precursor of tNEPC is still
debated, but a common clonal origin from adenocarcinoma
CRPC (adeno-CRPC) is likely [2]. The assumption of
negligible androgen signalling in these tumours implies
resistance to agents such as abiraterone and enzalutamide. In
this setting, research focused on identifying biomarkers of
tNEPC is to be welcomed.
Heck et al. [4] determined the prognostic impact of elevated
circulating neuroendocrine biomarkers chromogranin A
(CGA) and neuron-speciﬁc enolase (NSE) in the serum of
patients with CRPC treated with abiraterone in the post-
chemotherapy setting. Although CGA and NSE did not
predict PSA response, they correlated with clinical and
radiographic progression-free survival (PFS), as well as
overall survival (OS). The association between these
biomarkers and clinical outcomes in metastatic CRPC has
been conﬁrmed in retrospective studies [5]. According to the
authors, this association, independently of PSA response,
underlines the sub-clonality of this disease, and the key role
of androgen receptor (AR) signalling, even in advanced
disease [4].
The marker NSE is considered to be generic, with high
sensitivity but low speciﬁcity; CGA is a more speciﬁc
neuroendocrine tumour biomarker and a common
constituent of neuroendocrine tumour secretory granules.
Abnormal CGA levels have, however, been signiﬁcantly
associated with intake of proton pump inhibitors in patients
treated with abiraterone for metastatic CRPC rather than with
duration of treatment [5]. Unfortunately, the use of proton
pump inhibitors in that study was not disclosed and may
have affected the reported results. Moreover, compared with
previous experience, the rate of abnormal NSE was signiﬁcant
higher, probably in keeping with the low speciﬁcity of this
biomarker.
Interestingly, the authors report an OS and PFS of 12.7 and
3.7 months, respectively [4]. These data are signiﬁcantly
different from the results of the COU-AA 301 study, in
which treatment with abiraterone resulted in improved OS
(14.8 vs 10.9 months) [6]. Surprisingly, there was no
difference in PFS between abiraterone in the study by Heck
et al. and the control arm of the COU-AA 301 trial (3.6
months) [6]. This discordance could be attributable to the
small sample size of their study rather than the high PSA
level at initiation of abiraterone, as claimed by the authors. In
support of this alternative possibility, a post hoc analysis of
the AFFIRM trial [7] showed consistent beneﬁts in OS and
PFS with second-generation hormonal treatments, regardless
of baseline disease severity as assessed by PSA level.
Nevertheless, identifying patients with tNEPC is an urgent
clinical need; genomic germline and somatic DNA next-
generation sequencing as well as transcriptomic analysis of
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metastatic biopsies should now be considered a key approach
to better understanding the heterogeneity of metastatic CRPC
and to personalize treatment in order to maximize beneﬁt.
There is substantial genomic overlap between adeno-CRPCs
and tNEPC. TMPRSS2-ERG is the most common genomic
aberration in prostate cancer and has been reported in NEPC
with a similar frequency [2]. Furthermore, both adeno-CRPCs
and tNEPCs are enriched for the inactivation of key tumour
suppressor genes, such as RB1 and TP53, compared with
hormone-sensitive prostate cancer, albeit in different
proportions [2]. Although genomic ampliﬁcation and
activating point mutations of the AR in tNEPCs are notably
absent, the presence of AR-splicing variants, including ARv7,
is still detectable, suggesting that AR signalling is still present
in at least a proportion of tNEPCs [2].
Despite a common background of genomic aberrations,
tNEPCs have also been reported to have signiﬁcant
overexpression and copy number gains of AURKA and
MYCN (40% of NEPC vs 5% of primary prostate cancer
tumours), although these ﬁndings remain unsubstantiated [3].
As such, these have been postulated to be drivers of this
disease phenotype and are under investigation as targets of
novel agents.
Genome-wide DNA methylation analysis has, however, also
shown that there are marked epigenetic differences between
NEPC and adeno-CRPC, suggesting that epigenetic modiﬁers
play a major role in the induction and maintenance of the
neuroendocrine status [2].
In conclusion, the identiﬁcation and deﬁnition of NEPC
remains challenging. Blood biomarkers such as NSE and
CGA cannot be considered to be proven prognostic
biomarkers of NEPC as they have only been evaluated in
small retrospective studies not adhering to REMARK criteria
[8]. Genomic proﬁling from tissue biopsies or circulating
DNA remains a preferable way to identify NEPC and is
increasingly feasible, although still not affordable or a
standardized procedure for the deﬁnition of NEPC.
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Quality improvement in cystectomy care with
enhanced recovery (QUICCER) study
Enhanced recovery after surgery (ERAS) is a
multidisciplinary, multi-element care pathway approach that
aims to standardise and improve perioperative management.
Since the ﬁrst publication on ERAS for radical cystectomy in
the BJUI in 2008, the literature on this important factor in
postoperative management of patients undergoing major
surgery in the ﬁeld of urology is rather scarce and mainly in
form of reviews [1]. This clearly reﬂects the very slow
adoption of this approach, the reasons for which remain
unclear.
Baack Kukreja et al. [2] in this issue of BJUI performed an
analysis of sequential patients, before and after introduction
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